CINDY CHANG: Open Payments
NPI 1316561236 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,259 in 144 payments from 23 companies in 2025. Trend: 2023 $2,909 · 2024 $2,745 · 2025 $3,259
Food & beverage: $3,259
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $770 |
| Janssen Biotech, Inc. | 18 | $425 |
| Aimmune Therapeutics, Inc. | 22 | $349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $258 |
| Ardelyx, Inc. | 9 | $246 |
| GENZYME CORPORATION | 7 | $236 |
| Madrigal Pharmaceuticals | 7 | $185 |
| Ipsen Biopharmaceuticals, Inc | 6 | $171 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $149 |
| Gilead Sciences, Inc. | 6 | $102 |
Products named: TREMFYA, LINZESS, DUPIXENT, IBSRELA, ENTYVIO, REZDIFFRA, VOWST, IQIRVO.
Industry payments across AZ — which companies pay providers there.
